ASPR Prepares for Changing Landscape of Mpox Response at Home and Abroad

Since the beginning of the mpox outbreak in 2022, ASPR has worked closely with partners in the federal government and across the country to provide vaccines and therapeutics to protect and treat those who may be impacted by the disease – shipping over one million vials of the JYNNEOS vaccine and over 40,000 treatment courses of TPOXX, TEMBEXA, and VIG-IV from the Strategic National Stockpile (SNS).

Learn more and read the full blog post from ASPR.